DEF: NovoCure 2026 Annual Meeting Proxy Statement

NovoCure Limited has filed its definitive proxy statement for the 2026 Annual General Meeting of Shareholders to be held on June 3, 2026.

Summary

• The Annual General Meeting is scheduled for June 3, 2026, in St. Helier, Jersey.
• Shareholders will vote on the election of eleven directors, the appointment of Kost Forer Gabbay & Kasierer (EY Global) as auditor, an advisory vote on executive compensation, and the approval of the Amended and Restated 2024 Omnibus Incentive Plan.
• The company reported 2025 annual net revenues of $655 million, an 8% increase over 2024.
• As of December 31, 2025, the company had $448 million in cash, cash equivalents, and short-term investments.
• Active patients using Optune Gio and Optune Lua reached 4,620 at year-end 2025, a 12% increase from 2024.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive filing. While the company shows solid operational growth and clinical progress, the underperformance of Optune Lua and the net loss indicate ongoing challenges in scaling the business.

Positives

• Annual net revenues grew 8% to $655 million in 2025.
• Active patient base for TTFields therapy increased by 12% year-over-year.
• Successful Phase 3 clinical trial results for PANOVA-3 (pancreatic cancer) and METIS (brain metastases) met primary endpoints.
• Regulatory progress achieved with CE Mark for Optune Lua in Germany and approval in Japan for NSCLC treatment.
• Strong shareholder support for executive compensation in 2025, with 97.5% of votes cast in favor.

Negatives

• Optune Lua active patient numbers significantly underperformed expectations.
• The company's share price was negatively impacted during 2025.
• The LUNAR-4 clinical trial was discontinued in August 2025.
• The company reported a net loss of $136 million for 2025.

Risks

• Intense competition for talent in the medical device and biopharmaceutical sectors.
• Reliance on the success of the TTFields platform and clinical trial outcomes.
• Potential for future regulatory hurdles or delays in product approvals.
• Risks associated with international operations and currency exchange rate fluctuations.
• Cybersecurity threats and data privacy compliance requirements.

Future Outlook

The company intends to continue driving commercial adoption of its TTFields devices, advancing its clinical and product development pipelines, and maintaining its focus on long-term profitable growth. The company anticipates the requested share pool increase will cover equity compensation needs for approximately the next two years, until 2028.

Management Comments

• The Board believes the separation of Executive Chairman and CEO roles is optimal for long-term growth.
• Management emphasizes that the Amended Plan is critical to attracting and retaining talent in a highly competitive market.
• The company remains committed to its mission of extending survival in aggressive forms of cancer.

Industry Context

StockSavvy.ai notes that NovoCure continues to operate in a unique niche as a commercialized oncology medical device company. The focus on expanding the TTFields platform into new indications like pancreatic cancer and brain metastases aligns with broader industry trends of seeking novel, non-pharmacological cancer therapies. The company's emphasis on long-term equity incentives reflects the high-risk, long-cycle nature of medical device development.

Comparison to Industry Standards

• The company benchmarks its compensation against a peer group of similarly-sized medical device and biopharmaceutical companies, including 10x Genomics, Insulet, and Exact Sciences.
• The board composition (73% independent) and governance practices (separate Chair/CEO, clawback policies) align with standard practices for high-growth public companies.
• The use of performance-based equity awards (PSUs) is consistent with industry standards for aligning executive interests with long-term shareholder value.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed in the filing.

Related Party Transactions

• None disclosed in the filing beyond standard compensation arrangements.

Stakeholder Impact

• Shareholders are asked to approve an increase in the share reserve, which may result in dilution.
• Employees and executives continue to be incentivized through the company's equity-based compensation programs.
• Patients remain the focus of the company's clinical and product development efforts.

Next Steps

• Hold the Annual General Meeting of Shareholders on June 3, 2026.
• Tabulate and announce voting results via Form 8-K within four business days of the meeting.
• Implement the Amended and Restated 2024 Omnibus Incentive Plan if approved by shareholders.

Key Dates

Recommendation

The company is in a transition phase with new leadership and significant clinical trial milestones achieved, but it faces challenges in commercial adoption for certain products and remains unprofitable. A hold recommendation is appropriate until there is clearer evidence of sustained commercial success and a path to profitability.

Keywords

NovoCure, NVCR, Tumor Treating Fields, TTFields, Oncology, Proxy Statement, Executive Compensation, Medical Devices